SILVER SPRING
FDA approves LYTENAVA for neovascular
- Sponsor
- Outlook Therapeutics $OTLK
- Drug
- LYTENAVA · bevacizumab-vikg
- Indication
- neovascular (wet) age-related macular degeneration
FDA approved Outlook Therapeutics's LYTENAVA (bevacizumab-vikg) for neovascular (wet) age-related macular degeneration on 2026-07-21.
What this means
LYTENAVA is an eye-injection version of the cancer drug bevacizumab, which blocks a protein that drives abnormal blood vessel growth in wet macular degeneration. Today the FDA approved it specifically for treating this vision-threatening eye condition. This gives doctors a new, formally approved option for a medicine they have often used off-label to prevent blindness in older adults.